Leading IP Attorneys from Allergan, Sandoz, and Teva Join ACI's Hatch-Waxman Advisory Board

American Conference Institute (ACI) is pleased to announce that Debra Condino, Senior Vice President Chief Intellectual Property Counsel, Allergan, Inc.; Brian Hirsch, Head, US Patent Litigation, Sandoz Inc.; and Staci Julie, SVP and Chief IP Counsel, Teva Pharmaceuticals have joined ACI’s Hatch-Waxman Advisory Board and will speak at ACI’s 10th Annual Paragraph IV Disputes conference…

September Conference Materials are Now Available!

September was a productive month for ACI’s conference attendees. At our events, decision makers had the chance to acquire top notch industry information; ranging from the latest trends, developments, hottest litigation cases to key insights from leading experts and more. You now have the opportunity to remain ahead of the curve too by accessing conference materials.…

Husch Blackwell leads the charge in first inter partes review wins against pharmaceutical-related patents

Expert article by Joseph E. Cwik and Josh Nosal on July 2, 2014. Originally published on Healthcare Law Insights, reposted with the permission of Joseph E. Cwik. The Patent Trial and Appeal Board (PTAB) issued its first final written decisions June 20, 2014, in four inter partes reviews (IPR) of pharmaceutical-related patents. The four decisions…

The Law on Damages In Generic Drug Launches Remains Vague

Expert Guest Entry by David Manspeizer, Originally published on The New York Law Journal  It was a stunning number, purportedly the largest patent settlement in history. During trial, defendants Teva ($1.6 billion) and Sun ($550 million) agreed to pay plaintiffs Wyeth and Nycomed a combined $2.15 billion to settle litigation stemming from their “at-risk” launches of…